| Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines … RA Sperling, PS Aisen, LA Beckett, DA Bennett, S Craft, AM Fagan, ... Alzheimer's & dementia 7 (3), 280-292, 2011 | 8017 | 2011 |
| NIA-AA research framework: toward a biological definition of Alzheimer's disease CR Jack Jr, DA Bennett, K Blennow, MC Carrillo, B Dunn, SB Haeberlein, ... Alzheimer's & Dementia 14 (4), 535-562, 2018 | 7325 | 2018 |
| Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects LM Shaw, H Vanderstichele, M Knapik‐Czajka, CM Clark, PS Aisen, ... Annals of neurology 65 (4), 403-413, 2009 | 2246 | 2009 |
| Unified Huntington's disease rating scale: reliability and consistency K Kieburtz, JB Penney, P Como, N Ranen, A Feigin, D Abwender, ... Movement disorders 11 (2), 136-142, 1996 | 2001 | 1996 |
| Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease RS Doody, RG Thomas, M Farlow, T Iwatsubo, B Vellas, S Joffe, ... New England Journal of Medicine 370 (4), 311-321, 2014 | 1757 | 2014 |
| A phase 3 trial of semagacestat for treatment of Alzheimer's disease RS Doody, R Raman, M Farlow, T Iwatsubo, B Vellas, S Joffe, K Kieburtz, ... New England Journal of Medicine 369 (4), 341-350, 2013 | 1292 | 2013 |
| Trial of solanezumab for mild dementia due to Alzheimer’s disease LS Honig, B Vellas, M Woodward, M Boada, R Bullock, M Borrie, K Hager, ... New England Journal of Medicine 378 (4), 321-330, 2018 | 966 | 2018 |
| Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup RA Sperling, CR Jack Jr, SE Black, MP Frosch, SM Greenberg, BT Hyman, ... Alzheimer's & Dementia 7 (4), 367-385, 2011 | 684 | 2011 |
| The Alzheimer's disease neuroimaging initiative: progress report and future plans MW Weiner, PS Aisen, CR Jack Jr, WJ Jagust, JQ Trojanowski, L Shaw, ... Alzheimer's & Dementia 6 (3), 202-211. e7, 2010 | 494 | 2010 |
| Rate of functional decline in Huntington’s disease K Marder, H Zhao, RH Myers, M Cudkowicz, E Kayson, K Kieburtz, ... Neurology 54 (2), 452-452, 2000 | 448 | 2000 |
| Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease AS Fleisher, R Raman, ER Siemers, L Becerra, CM Clark, RA Dean, ... Archives of neurology 65 (8), 1031-1038, 2008 | 434 | 2008 |
| Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients ER Siemers, KL Sundell, C Carlson, M Case, G Sethuraman, H Liu-Seifert, ... Alzheimer's & Dementia 12 (2), 110-120, 2016 | 428 | 2016 |
| Practice effects and the use of alternate forms in serial neuropsychological testing LJ Beglinger, B Gaydos, O Tangphao-Daniels, K Duff, DA Kareken, ... Archives of Clinical Neuropsychology 20 (4), 517-529, 2005 | 423 | 2005 |
| Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease ER Siemers, JF Quinn, J Kaye, MR Farlow, A Porsteinsson, P Tariot, ... Neurology 66 (4), 602-604, 2006 | 421 | 2006 |
| A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system RJ Bateman, ER Siemers, KG Mawuenyega, G Wen, KR Browning, ... Annals of Neurology: Official Journal of the American Neurological …, 2009 | 370 | 2009 |
| Biological markers for therapeutic trials in Alzheimer’s disease RA Frank, D Galasko, H Hampel, J Hardy, MJ de Leon, PD Mehta, ... Neurobiology of aging 24 (4), 521-536, 2003 | 354 | 2003 |
| Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease M Farlow, SE Arnold, CH Van Dyck, PS Aisen, BJ Snider, ... Alzheimer's & Dementia 8 (4), 261-271, 2012 | 337 | 2012 |
| Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects JQ Trojanowski, H Vandeerstichele, M Korecka, CM Clark, PS Aisen, ... Alzheimer's & dementia 6 (3), 230-238, 2010 | 333 | 2010 |
| Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI LM Shaw, H Vanderstichele, M Knapik-Czajka, M Figurski, E Coart, ... Acta neuropathologica 121, 597-609, 2011 | 324 | 2011 |
| Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers E Siemers, M Skinner, RA Dean, C Gonzales, J Satterwhite, M Farlow, ... Clinical neuropharmacology 28 (3), 126-132, 2005 | 306 | 2005 |
